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A sequence variant on 17q21 is associated with age
at onset and severity of asthma
Eva Halapi1, Daniel F Gudbjartsson1, Gudrun M Jonsdottir1, Unnur S Bjornsdottir1,2, Gudmar Thorleifsson1,
Hafdis Helgadottir1, Carolyn Williams3,4,5, Gerard H Koppelman6, Andrea Heinzmann7, H Marike Boezen8,
Aslaug Jonasdottir1, Thorarinn Blondal1, Sigurjon A Gudjonsson1, Adalbjorg Jonasdottir1,
Theodora Thorlacius1, Amanda P Henry9, Janine Altmueller10, Marcus Krueger7, Hyoung Doo Shin11,12,
Soo-Taek Uh13, Hyun Sub Cheong12, Brynja Jonsdottir14, Bjorn R Ludviksson2,15, Dora Ludviksdottir16,
David Gislason16, Choon-Sik Park17, Klaus Deichmann7, Philip J Thompson3,4,5, Matthias Wjst18,19,
Ian P Hall9, Dirkje S Postma20, Thorarinn Gislason2,16, Augustine Kong1, Ingileif Jonsdottir1,2,15,
Unnur Thorsteinsdottir*,1,2 and Kari Stefansson*,1,2
A sequence variant (rs7216389-T) near the ORMDL3 gene on chromosome 17q21 was recently found to be associated with
childhood asthma. We sought to evaluate the effect of rs7216389-T on asthma subphenotypes and its correlation with
expression levels of neighboring genes. The association of rs7216389-T with asthma was replicated in six European and one
Asian study cohort (N¼4917 cases N¼34589 controls). In addition, we found that the association of rs7216389-T was
confined to cases with early onset of asthma, particularly in early childhood (age: 0–5 years OR¼1.51, P¼6.89 .109) and
adolescence (age: 14–17 years OR¼1.71, P¼5.47 .109). A weaker association was observed for onset between 6 and
13 years of age (OR¼1.17, P¼0.035), but none for adult-onset asthma (OR¼1.07, P¼0.12). Cases were further stratified by
sex, asthma severity and atopy status. An association with greater asthma severity was observed among early-onset asthma
cases (P¼0.0012), but no association with sex or atopy status was observed among the asthma cases. An association between
sequence variants and the expression of genes in the 17q21 region was assessed in white blood cell RNA samples collected
from Icelandic individuals (n¼743). rs7216389 associated with the expression of GSDMB and ORMDL3 genes. However, other
sequence variants showing a weaker association with asthma compared with that of rs7216389 were more strongly associated
with the expression of both genes. Thus, the contribution of rs7216389-T to the development of asthma is unlikely to operate
only through an impact on the expression of ORMDL3 or GSDMB genes.
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INTRODUCTION
Multiple environmental and hereditary factors affect the development
of asthma.1–3 More than 200 genes have been reported to harbor
sequence variants that associate with asthma or related phenotypes,
but few have been robustly replicated.4,5 In a recent genome-wide
association study of asthma, the sequence variant rs7216389-T on
chromosome 17q21 was shown to associate with the risk of childhood
asthma.6 rs7216389 is located in an intron of the GSDMB gene
(encoding the gasdermin-like protein), but its association with asthma
was originally linked to the expression of the nearby ORMDL3 gene
(encoding the ORM1-like 3 protein). Subsequent reports have
provided further support for the association of this 17q21 locus
with childhood7–11 and persistent asthma,12 but the mechanisms
underlying this effect remain unclear.
Asthma is a heterogeneous disease with respect to age at onset,
clinical presentation, disease progression and therapeutic response.3
To investigate the phenotype–genotype relationship of the sequence
variant at 17q21 with asthma, we genotyped tagging SNPs at this locus
(including rs7216389) in samples obtained from Iceland, Australia,
The Netherlands, Germany, the United Kingdom and Korea with
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information on age at onset, sex, asthma severity and atopy status.
We also examined the correlation of those SNPs with the expression
of genes in the region around rs7216389 in white blood cells of
an Icelandic sample set.
METHODS
Study samples
The samples used in this study consisted of case–control sample sets obtained
from Iceland, Germany, The Netherlands, the United Kingdom, Australia and
Korea, and a familial sample set from Germany (Table 1). Informed consent
was obtained locally from all participants and all studies were approved by the
local ethics committees. The individual sample sets have been described in
detail elsewhere13–24 (see also brief cohort descriptions in Supplementary text).
For all sample sets, a diagnosis of asthma based on patient symptoms and
clinical testing was given by a physician at each local clinical center on the basis of
international and national asthma guidelines. Atopy status (defined by at least one
positive response to allergens) as determined by skin prick testing was available for
all samples, except the UK set. Asthma severity was available in the Icelandic,
Australian and UK sample sets. In the Icelandic cases, asthma severity was assessed
using criteria from the National Heart, Lung and Blood Institute (NHLBI)25 and
GINA guidelines.26 In addition, patient charts were reviewed specifically for
frequency of daytime and nocturnal symptoms and impact on daily activities,
asthma-related health-care use (use of emergency care, hospitalizations and
physician office visits), medication use (dose of inhaled corticosteroids) and use
of add-on medications such as long- and short-acting b-agonists, systemic
corticosteroids, theophylline and leukotriene antagonists. The criteria used to
assess asthma severity in the Australian sample set were described previously.17
Briefly, the clinical parameters used for severity scoring included lung function (%
predicted FEV1), use of oral corticosteroids, daily inhaled corticosteroid dose,
weekly frequency of use of rescue medication, weekly frequency of daytime
symptoms, weekly frequency of nighttime wakening because of asthma, unplanned
visits to a general practitioner and hospital admissions for asthma in the preceding
12 months. On the basis of national27 and NHLBI guidelines,25 patients were
classified as mild, moderate or severe for each criterion and the most common
classification was used as a measure of asthma severity. For the UK cohort, severity
assessment was based on the British Thoracic Society guidelines.28 Steps 1–2 were
considered as mild, step 3 was as considered moderate and steps 4–5 were
considered as severe asthma.
Information on age at onset of asthma and sex was available for all sample
sets, except for the Germany I set. Early onset was defined as the onset of
asthma at or under 18 years of age, and adult onset was defined as the onset at
or over 19 years of age in all study sample sets. In Iceland, the age at onset was
assessed with a questionnaire using the question ‘How old were you when you
had your first asthma-attack?’ For the Australian and UK sample sets, the age at
onset was assessed with questionnaires and a subsequent interview using the
question ‘How old were you when you were diagnosed with asthma?’ For the
Korean and Dutch sample sets, the age at onset was assessed with a ques-
tionnaire using the question ‘How old were you when you first experienced
asthma symptoms?’ For the Germany II sample set, the age at onset was
assessed with a parental interview asking for the age at occurrence of wheezing.
Total serum IgE levels were measured by UniCAP FEIA (Pharmacia Upjohn,
Uppsala, Sweden).
Genotyping
All genotyping procedures of SNPs in the 17q21 region were carried out
at deCODE Genetics using Hap300 bead-array (Illumina Inc., San Diego,
CA, USA), TaqMan (Applied Biosystems Inc., Cheshire, UK) or
Centaurus platforms (NanoGen Inc., San Diego, CA, USA). In Iceland, 1192
asthma patients and 30 237 controls were genotyped with the Illumina 300K
chip. An additional 456 Icelandic asthma patients and 661 Icelandic controls
and all non-Icelandic samples were genotyped using either single SNP TaqMan
or Centaurus platforms. The SNPs used in the 17q21 region on the Illumina
300K chip passed quality filters (yield 495%, minor allele frequency 40.01,
no distortion of Hardy–Weinberg equilibrium (HWE) in the controls
(P41.010–3)). All samples had call rates above 98%. The quality of TaqMan
or Centaurus SNP assays was evaluated by genotyping each assay in the CEU
HapMap samples and comparing the results with the publicity released
HapMap data. Assays with41.5% mismatch rate were not used. Supplemen-
tary Table 2 contains allele frequencies and HWE P-values for the different
sample sets.
Expression analysis
Expression levels for genes in the 17q21 region and correlation with the
genotype status of 15 SNPs in the region were assessed with Human 25K chip
array (Agilent Technologies Inc.) as part of a separate study in Iceland29
(expression data available as GEO data set GSE7695 and GPL3991). The
collection of white blood cell samples (N¼743), mRNA isolation and expres-
sion profiling have been described previously.29 Expression was quantified as
mean logarithm (log10) expression ratio (MLR), that is, expression ratios
compared with background-corrected intensity values.29 The array expression
data were validated by performing TaqMan gene expression assays for IKZF3
(encoding the IKAROS family zinc-finger 3 protein), GDSM1 (encoding
the gasdermin 1 protein), ZPBP2 (encoding the zona pelliculada-binding
protein 2), GSDMB and ORMDL3 genes using cDNA derived from the same
white blood cell RNA samples from individuals tested on the Agilent chip.
TaqMan assays for ZPBP2 and GDSM1 did not yield any product in white
blood cells or other cDNA source tested (data not shown). TaqMan gene
expression assays were also performed on mRNA from Epstein–Barr Virus
Table 1 Study populations
Iceland Australia The Netherlands Korea United Kingdom Germany I Germany II
Recruitment phenotype Asthma Asthma Asthma Asthma Asthma Childhood/adolescent asthma Childhood asthma
Study design Case–control Case–control Case–control Case–control Case–control Case–control Affected
Sib-pairs
N cases/controls 1648/30 898 647/564 221/1564 1387/558 292/241 307/560 415/204a
Male/femaleb 475/1173 244/403 136/85 588/799 116/176 198/109 240/175
N age at onsetb
Early/adult/unknown c 617/744/287 370/226/51 156/57/8 211/1176/0 138/60/94 307/0/0 415/0/0
N atopyb
Atopic/nonatopic/unknown 890/697/61 539/106/2 181/31/9 829/541/17 NAe 277/30/0 319/96/0
Log10 total serum IgE
b,d 1.7±0.7 2.0±0.6 2.0±0.6 2.2±0.6 NA 2.4±0.6 2.3±0.7
N severity scoreb
Mild/moderate/severe/unknown 547/537/118/446 336/233/78/0 NA NA 28/73/65/126 NA NA
aAn estimate of the number of untransmitted parental alleles were used as control alleles.
bVariables related to cases only.
cEarly onset¼at or younger than 18 years of age; adult onset¼at 19 years of age or older.
dMean±s.d.
eNot available.
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(EBV)-transformed B lymphocytes30 from Icelandic prostate cancer patients
(N¼186) and from peripheral blood mononuclear cells (PBMCs) isolated
from Icelandic patients with asthma (N¼182).31 cDNA was synthesized using
the high-capacity cDNA reverse transcriptase kit (Applied Biosystems Inc.).
TaqMan expression assays were performed with the TaqMan Universal PCR
Master Mix (Applied Biosystems Inc.), using PCR primers from Eurofins mwg
operon (Ebersberg, Germany) and MGB TaqMan probes (Applied Biosystems
Inc.) (for primer and probe sequences, see Supplementary Table 1).
Statistical analysis
To replicate the previously reported association of chromosome 17q21 SNPs
with asthma, we tested their association with asthma within each population. We
then explored whether the strength of association depended on the age at onset
of asthma by breaking the sample sets into children, adults with early onset and
adults with adult onset (Table 2). We further studied the effect of age at onset by
testing the association within 2-year age bins (Figure 1). On the basis of the
results of the age-stratified analysis, subsequent testing was performed separately
within early- and adult-onset groups. We then examined whether the association
with asthma depended on sex, asthma severity, atopy status and IgE levels.
For association analysis, we used standard likelihood ratio statistics, imple-
mented in the NEMO software,32 to calculate two-sided P-values and allele-
specific ORs for each individual allele, assuming a multiplicative model (the
two alleles are independent, or in HWE, within the population of affected
individuals). Allele frequencies were estimated by maximum likelihood and
calculated directly for the observed data, and tests of differences between cases
and controls were performed using a generalized likelihood ratio test.32
The sib-pairs from the Germany II sample set were analyzed assuming
Mendelian inheritance under the null hypothesis. Under alternative transmis-
sion, probabilities were defined by the multiplicative risk model and allele
frequencies. Untransmitted parental alleles were used as controls. The number
of untransmitted parental genotypes corresponds to having genotyped 204
control individuals on an average.
A test for severity among cases was conducted by logistic regression, treating
allele counts as the response variable and the severity class as an explanatory
variable, encoding the severity classes as 0 (mild), 1 (moderate) and 2 (severe).
Results obtained from multiple groups were combined using a Mantel–
Haenszel model33 that allows for analysis incorporating disparate frequencies
for alleles and genotypes for different populations, but assuming the same
relative risks. Tests of heterogeneity were conducted by assuming that the allele
frequencies were the same in all groups under the null hypothesis, but that each
group had a different allele frequency under the alternative hypothesis.
The correlation between the expression ratios (MLR)29 for the genes
analyzed and genotypes of each of the SNPs in the locus was tested by
regressing MLRs against the SNPs’ allele count after adjustment for age and sex.
Multiple logistic regression was used to test the association of SNPs with
asthma, conditional on another SNP’s association with asthma. Similarly,
multiple linear regression was used to test the association of an SNP with
quantitative expression levels, conditional on another SNP’s association with
the expression levels.
RESULTS
Disease association
We replicated the previously reported association of allele T of
rs7216389 with asthma6 in 1648 Icelandic asthma cases and 30 898
Icelandic controls (OR (95%CI)¼1.23 (1.14–1.33), P¼1.56107).
The effect in Iceland was weaker than the previously reported ORs of
1.456 and 1.508 in asthmatic patients of European descent. Previous
studies were predominantly conducted in pediatric cohorts, whereas
in the Icelandic sample set, the cases are adults.6,11 We therefore
assessed the strength of the association with rs7216389-T stratified on
age at onset of asthma, dividing the cases into early onset (before or at
18 years of age n¼617) and adult onset (at or after 19 years of age
n¼744). Early-onset cases showed a substantially stronger association
(OR (95%CI)¼1.44 (1.28–1.63)) than did adult-onset cases (OR
(95%CI)¼1.11 (0.99–1.23)) (Table 2). Ta
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We then assessed the association of rs7216389-T with asthma,
stratified by age at onset, in six additional sets of asthma patients:
Australian, Dutch and Korean sample sets consisting of adult asthma
cases, a UK sample set consisting of both adult and child asthma cases
and two German sample sets of childhood asthma cases (Table 1). As
in Iceland, the association of rs7216389-T with asthma was confined to
the early-onset cases (OR (95%CI)¼1.33 (1.21–1.46) for early-onset
asthma compared with OR (95%CI)¼1.02 (0.91–1.15) for
adult-onset asthma) (Table 2, Supplementary Table 3). The effect of
rs7216389-T in samples consisting of childhood asthma cases (OR
(95%CI)¼1.30 (1.13–1.50)) was similar to that seen for adult cases
with early-onset asthma (OR (95%CI)¼1.35 (1.19–1.52)).
Information on age at onset of asthma in years was available for
Iceland, the United Kingdom, Germany II, Australia and Korea. To
increase the resolution of the effect of age at onset of asthma, we
further assessed the association with rs7216389-T by grouping cases
into 2-year bins (0–1, 2–3, 4–5, 6–7 years and so on, up to over
70 years). Nominally significantly increased risk was observed for the
age bins 0–1, 2–3, 4–5, 14–15 and 16–17 years (Figure 1, Supplemen-
tary Table 4). Subsequent analysis of larger bins (0–5, 6–13, 14–17
years) within the early-onset-of-asthma group showed strong associa-
tion for the intervals 0–5 and 14–17 years at onset (OR (95%CI)¼1.51
(1.31–1.73), P¼ 6.89109 and OR (95%CI)¼1.71 (1.39–2.11),
P¼5.47109, respectively), whereas a weaker association was observed
in the age interval 6–13 years (OR (95%CI)¼1.17 (1.01–1.35),
P¼0.035). The Dutch and Germany I samples were only classified as
early or late onset and were therefore not included in the higher-
resolution age at onset analysis.
Given that the strength of association with rs7216389-T was
primarily observed in early-onset cases, we further examined whether
rs7216389-T associated with sex, asthma severity, atopy status and
serum IgE levels within early- and adult-onset cases. Asthma severity
scoring was available for the Icelandic, Australian and UK cases. In the
combined analysis of the early-onset cases, rs7216389-T correlated
positively with asthma severity (P¼0.0012, Table 3), with the effect in
the same direction for all three groups, although not significant in
the UK sample set. No association with severity was observed among
adult-onset asthma cases (P¼0.75, Supplementary Table 6). No asso-
ciation was observed with IgE (P¼0.35) or atopy status (P¼0.55)
(Supplementary Table 5), and no difference was observed between
male and female cases (P¼0.60).
Restricting the analysis to early-onset asthma cases, we then looked
for signals not accounted for by rs7216389-T. For this purpose,
association with 14 additional SNPs was assessed in the Icelandic,
Australian, UK and German samples, in which each marker was tested
by conditioning on the observed association with each of the other
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Figure 1 Association with rs7216389-T stratified by age at onset of asthma. Cases were stratified by age at onset, and association with rs7216389-T was
assessed for each age bin (0–1, 2–3, 4–5, 6–7 years and so on). Cases with onset at 70 years or older were pooled into one single bin (70+). The OR and
95% CI for the mean age of each bin for the combined sample set (Iceland, Australia, United Kingdom, Korea and Germany II) are plotted.
Table 3 Association results for the T allele of rs7216389 with early onset of asthma stratified by severity a
Mild Moderate Severe
Study group N control N cases OR (95% CI) N cases OR (95% CI) N cases OR (95% CI) P-value
Iceland 30898 200 1.37 (1.12, 1.67) 196 1.52 (1.25, 1.86) 27 2.86 (1.64, 4.98) 0.052
Australia 564 181 1.14 (0.90, 1.45) 138 1.28 (0.98, 1.67) 51 1.69 (1.12, 2.55) 0.099
UK 241 18 1.40 (0.71, 2.77) 35 1.61 (0.97, 2.67) 25 1.56 (0.87, 2.81) 0.47
Combined 31703 399 1.28 (1.10, 1.48) 369 1.45 (1.24, 1.68) 103 1.91 (1.43, 2.55) 0.0012
Shown are the number (N) of controls and cases, the OR with a 95% CI and two-sided P-value for regressing the severity status on rs7216389-T allele counts for the individual studies and the
combined study populations.
aOnset of asthma at or younger than 18 years of age. P-values for heterogeneity between effect size in sample groups were 0.47, 0.54 and 0.24 for mild, moderate and severe asthma, respectively,
in the combined analysis.
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markers (Supplementary Table 7). None of the markers remained
significant after adjusting for the association with rs7216389-T and
accounting for the number of SNPs tested.
Correlation between 17q21 sequence variants and gene expression
levels
The SNP rs7216389 is located within the GSDMB gene (Supplemen-
tary Figure 1). We assessed the association of rs7216389 with gene
expression levels by probes representing 29 refseq genes and 3 mRNA
sequences located 540 kb upstream and downstream of s7216389 in
white blood cell RNA obtained from Icelandic individuals (N¼743).29
The strongest association of rs7216389 was seen with the expression of
GSDMB and ORMDL3 genes (P¼2.31038 and P¼8.81058, respec-
tively, Table 4 and Supplementary Table 8). The expression of GSDMB
and ORMDL3 is correlated in white blood cells (observed correlation
r0.71; Supplementary Figure 2). We verified the association of
rs7216389 with expression levels by RT-PCR TaqMan assays for
GSDMB and ORMDL3 on the same RNA used for array experiments
and subsequently in additional RNA samples as well, which were
derived from PBMCs (N¼182) and EBV-transformed B-lymphocytes
(N¼186) (data not shown). Finally, we assessed whether sequence
variants other than rs7216389 associated more strongly with the
expression of ORMDL3 and GSDMB genes. After adjusting for the
effect of rs7216389 and correcting for multiple testing, 11 of the
14 markers tested remained significantly associated with ORMDL3
expression levels, whereas 9 markers remained significantly associated
with GSDMB levels (Po0.0036¼0.05/14, Table 4).
DISCUSSION
This study confirms the previously reported genome-wide association
of a sequence variant at 17q21 with asthma. We also show, using a
large sample including six sets of European and one of East-Asian
ancestry, that the variant is predominantly a risk factor for early-onset
asthma, whereas its association with adult-onset asthma is absent.
The risk associated with rs7216389-T was significant at 0–5 years and
14–17 years of age at the onset of asthma. The original discovery6 and
subsequent studies7–10 reported that the 17q21 locus is primarily
associated with pediatric asthma. In this study, we confirm and further
extend these findings by showing that association is not only confined
to cases with onset in early childhood but also to cases with onset in
adolescence.
Asthma is a phenotypically heterogeneous disease, with great
variation in symptom severity and frequency and in the age at
onset. One of the strengths of this multicenter study is that it includes
both child and adult asthma cases with early or adult onset with
variable disease severity, allowing for assessment of the risk contri-
buted by the 17q21 variant in multiple asthma subphenotypes. The
bimodal pattern of association with rs7216389-T with respect to age at
onset in all sample sets combined, as also observed for individual
sample sets (data not shown), suggests that the 17q21 locus not only
confers increased risk for developing asthma in early childhood as has
been reported,8 but also presents a substantial risk for onset of asthma
in adolescence.
In this study, all cases were diagnosed by a physician using
standardized international and national criteria. Although it cannot
be excluded that ascertainment criteria influenced the results, we
observed a consistent association of rs7216389-T with early-onset
asthma in all samples sets, but not with adult-onset asthma in any
sample set. It is unlikely that recall bias or differences in ascertainment
would result in the bimodal pattern observed. Self-reported year of
asthma onset by adults was accurate in cases with a clinical diagnosis
of asthma followed up after 10 years34 and in the longitudinal
European Community Respiratory Health Survey.35 High concor-
dance for reported age at onset with a self-administered questionnaire
Table 4 Association with early onset asthma and the expression of the ORMDL3 and GSDMB genes in white blood cells (N¼743) for 15
markers at 17q21, both unadjusted and adjusted for the effect of rs7216389-T
Association with early onset asthma Association with ORMDL3 expression Association with GSDMB expression
P-value P-value P-value
SNP Allele Position a OR Unadjusted rs7216389 adj. Unadjusted rs7216389 adj. Unadjusted rs7216389 adj.
rs2941504 A 35084 426 1.29 1.2108 0.032 3.61021 0.66 1.21011 0.31
rs907091 T 35175 268 1.34 1.71012 0.47 2.61060 3.4105 1.41042 8.3106
rs907092 G 35175 785 1.34 1.71012 0.18 51063 1.51010 5.11036 0.0012
rs9303277 C 35229 995 1.37 2.81014 0.09 8.31061 2.1105 1.11041 6.1105
rs3816470 T 35239 327 1.37 4.31014 0.031 1.31058 3.5105 2.41042 4.7106
rs11557467 G 35282 160 1.35 3.11013 0.45 5.41062 5.8106 1.51042 1.2105
rs8067378 A 35304 874 1.35 4.61013 0.72 5.41062 5.8106 1.51042 1.2105
rs2305480 C 35315 722 1.36 1.31013 0.12 9.11065 2.31010 5.51037 0.0030
rs2305479 G 35315 743 1.37 1.71014 0.11 7.71061 0.00016 6.81043 1.8106
rs2290400 A 35319 766 1.38 6.71015 0.018 1.21060 0.00029 1.31041 5.6105
rs7216389 T 35323 475 1.36 5.11014 — 8.81058 — 2.31038 —
rs4795405 C 35341 943 1.37 6.61014 0.018 5.81060 1.8108 1.21033 0.016
rs1007654 G 35364 880 1.32 6.91010 0.040 1.31028 0.1031 9.41016 0.84
rs3902025 A 35372 780 1.32 1.01010 0.050 8.61039 0.00030 5.51022 0.15
rs3894194 T 35375 519 1.32 3.91011 0.078 8.91034 0.03775 5.41020 0.59
The calculated association for early onset asthma is obtained by combining the study populations (Iceland, Australia, UK, Germany I and Germany II) using a Mantel–Haenszel model.
Log-transformed expression levels of ORMDL3 and GSDMB were corrected for age and sex. Correlation between MLR and allele count was performed treating the corrected log expression level
as the response variable and the allele as the explanatory variable for each of the 15 markers. Shown are the OR and two-sided P-values, unadjusted and adjusted when the association is tested
conditional on the observed association to SNP rs7216389.
aBase pair position March 2006 human reference sequence (NCBI Build 36).
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and face-to-face interview was also noted in the Epidemiological Study
on Genetics and Environment of Asthma.8 Imperfect recall may dilute
the age bins in which the 17q21 variant has an effect, but is unlikely to
shift these ages from early childhood to adolescence. The same would
apply for differences in ascertainment for age at onset. Most indivi-
duals diagnosed with asthma in the first two decades of life have had
recurrent wheezing episodes in early childhood,36,37 suggesting that
the disease process may start years before diagnosis. Thus, cases with
onset in adolescence may have had asthma-related symptoms such
as bronchial hyperresponsiveness or wheezing episodes during child-
hood, or alternatively, changes in environmental exposure during
adolescence could trigger asthma onset in susceptible individuals.
The adolescent period is associated with changes in social behavior,
such as initiation of smoking. Bouzigon et al 8 reported that 17q21
variants were associated with substantially increased risk for asthma in
children exposed to environmental smoke, and regular smoking has
been associated with increased risk of new-onset asthma in adoles-
cents.38 Our study was neither sufficiently powered nor detailed
enough with respect to information on smoking initiation and
duration to examine the relation of smoking pattern and risk for
asthma associated with rs7216389-T in 14-to17-year-old subjects.
rs7216389-T correlated with asthma severity in early onset in the
three sample sets analyzed, but not with adult-onset cases. This is in
line with results obtained from two recent studies that reported an
association of the rs7216389 T/T homozygote state with more
frequent asthma exacerbations7,11 and hospitalizations.11 Asthma
severity is a complex composite phenotype39 based on the frequency
and severity of asthma symptoms, as well as on lung function and
treatment response.25,26 Most asthma patients with mild-to-moderate
asthma can adequately control symptoms with standard therapies, but
an estimated 5–10% of patients with severe asthma are largely
unresponsive to typical therapies, including corticosteroids.40 Disease
severity contributes to a large portion of morbidity in asthma.41 Our
demonstration that rs7216389-T associates with severity in early-onset
asthma could contribute to an earlier identification of individuals at
high risk of developing severe asthma, allowing for more appropriate
therapy at an earlier stage. Moffatt et al 6 demonstrated that rs7216389
correlates with the expression of ORMDL3, and suggested that
rs7216389-T confers the risk of asthma by affecting the expression
of the ORMDL3 gene. We confirmed the association of rs7216389-T
with expression levels of ORMDL3, and extended this observation to
its association with the expression of the GSDMB gene, in which
rs7216389 is located. We also found that the expression of these genes
is highly correlated, suggesting that they may be coregulated. Several
sequence variants at 17q21 associating with asthma affect expression
levels of both GSDMB and ORMDL3. We showed that the variants
with the strongest association with asthma were different from those
that were most strongly associated with the expression of ORMDL3 or
GSDMB. Furthermore, we observed a significant residual association
for many markers with expression levels of ORMDL3 or GSDMB after
adjusting for the effect of rs7216389. This shows that an alteration of
the expression levels of either of these genes is unlikely to constitute
the sole mechanism by which 17q21 sequence variants contribute to
asthma susceptibility.
Given the relatively strong LD at this locus, we examined key SNPs
tagging the region for association with early-onset asthma. However,
after adjusting for the effect of rs7216389-T, association with other
markers was nonsignificant. Two recent studies found no significant
association of rs7216389-T with asthma in African-American
patients,10,42 which, given the difference in LD structure in European
and African Americans, suggests that rs7216389-T is not the causal
variant itself and that the causal variant is in lower LD with
rs7216389-T in African Americans. Recently, other SNPs highly
correlated with rs7216389 were found to be associated with Crohn’s
disease (rs2872507)43 and type I diabetes (rs2290400),44 indicating
that sequence variants at the 17q21 locus may be involved in
mechanisms regulating immune responses. Further studies focusing
on both gene and protein expression in relevant tissues and/or
appropriate asthma models with extended phenotypic and genetic
refinement are warranted to elucidate the precise mechanisms by
which the 17q21 sequence variation contributes to asthma.
In summary, in addition to robustly replicating sequence variants
that associate with asthma at the 17q21 locus, our data demonstrate
that they confer a different risk of development of asthma at early age
compared with onset at adult age in cases of European and Asian
ancestry. The 17q21 locus associated with disease severity among
early-onset but not adult-onset cases. We further show that the
sequence variants showing the strongest association with asthma are
different from those best associated with the expression of ORMDL3
or GSDMB. This suggests that the contribution of this locus to asthma
susceptibility is unlikely to operate only through the expression of
ORMDL3 or GSDMB genes, and that other mechanisms, or genes,
contribute to the association.
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